Filtered By:
Condition: Heart Failure
Education: Study
Management: Hospitals
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 321 results found since Jan 2013.
Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients
Tex Heart Inst J. 2021 Jul 1;48(3):e207260. doi: 10.14503/THIJ-20-7260.ABSTRACTWe studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 ± 9.3 days (range, ≤48 d). Of 2...
Source: Texas Heart Institute Journal - August 13, 2021 Category: Cardiology Authors: Daniel W Nelson Sakthi Sundararajan Evan Klein Lyle D Joyce Lucian A Durham David L Joyce Asim A Mohammed Source Type: research
Determinants of atrial fibrillation after cardiac surgery
Rev Cardiovasc Med. 2021 Jun 30;22(2):329-341. doi: 10.31083/j.rcm2202040.ABSTRACTPost-operative Atrial fibrillation (POAF) is a common complication post cardiac surgery. It can result in detrimental short- and long-term outcomes due to the increased risk of stroke, cardiac arrest and congestive heart failure in addition to prolonged intensive care and total hospital stay raising the overall healthcare cost. Accurately identifying predictors and biomarkers for POAF ensures that patients at greatest risk can be given the appropriate prophylactic measures; resources can be distributed to the groups who are most in need and w...
Source: Reviews in Cardiovascular Medicine - July 14, 2021 Category: Cardiology Authors: Mashal Qureshi Ammaarah Ahmed Victoria Massie Ellenor Marshall Amer Harky Source Type: research
Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients
Tex Heart Inst J. 2021 Jul 1;48(3):e207260. doi: 10.14503/THIJ-20-7260.ABSTRACTWe studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 ± 9.3 days (range, ≤48 d). Of 2...
Source: Texas Heart Institute Journal - August 13, 2021 Category: Cardiology Authors: Daniel W Nelson Sakthi Sundararajan Evan Klein Lyle D Joyce Lucian A Durham David L Joyce Asim A Mohammed Source Type: research
Determinants of atrial fibrillation after cardiac surgery
Rev Cardiovasc Med. 2021 Jun 30;22(2):329-341. doi: 10.31083/j.rcm2202040.ABSTRACTPost-operative Atrial fibrillation (POAF) is a common complication post cardiac surgery. It can result in detrimental short- and long-term outcomes due to the increased risk of stroke, cardiac arrest and congestive heart failure in addition to prolonged intensive care and total hospital stay raising the overall healthcare cost. Accurately identifying predictors and biomarkers for POAF ensures that patients at greatest risk can be given the appropriate prophylactic measures; resources can be distributed to the groups who are most in need and w...
Source: Reviews in Cardiovascular Medicine - July 14, 2021 Category: Cardiology Authors: Mashal Qureshi Ammaarah Ahmed Victoria Massie Ellenor Marshall Amer Harky Source Type: research
Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients
Tex Heart Inst J. 2021 Jul 1;48(3):e207260. doi: 10.14503/THIJ-20-7260.ABSTRACTWe studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 ± 9.3 days (range, ≤48 d). Of 2...
Source: Texas Heart Institute Journal - August 13, 2021 Category: Cardiology Authors: Daniel W Nelson Sakthi Sundararajan Evan Klein Lyle D Joyce Lucian A Durham David L Joyce Asim A Mohammed Source Type: research
Determinants of atrial fibrillation after cardiac surgery
Rev Cardiovasc Med. 2021 Jun 30;22(2):329-341. doi: 10.31083/j.rcm2202040.ABSTRACTPost-operative Atrial fibrillation (POAF) is a common complication post cardiac surgery. It can result in detrimental short- and long-term outcomes due to the increased risk of stroke, cardiac arrest and congestive heart failure in addition to prolonged intensive care and total hospital stay raising the overall healthcare cost. Accurately identifying predictors and biomarkers for POAF ensures that patients at greatest risk can be given the appropriate prophylactic measures; resources can be distributed to the groups who are most in need and w...
Source: Reviews in Cardiovascular Medicine - July 14, 2021 Category: Cardiology Authors: Mashal Qureshi Ammaarah Ahmed Victoria Massie Ellenor Marshall Amer Harky Source Type: research
Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients
Tex Heart Inst J. 2021 Jul 1;48(3):e207260. doi: 10.14503/THIJ-20-7260.ABSTRACTWe studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 ± 9.3 days (range, ≤48 d). Of 2...
Source: Texas Heart Institute Journal - August 13, 2021 Category: Cardiology Authors: Daniel W Nelson Sakthi Sundararajan Evan Klein Lyle D Joyce Lucian A Durham David L Joyce Asim A Mohammed Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients
Tex Heart Inst J. 2021 Jul 1;48(3):e207260. doi: 10.14503/THIJ-20-7260.ABSTRACTWe studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 ± 9.3 days (range, ≤48 d). Of 2...
Source: Texas Heart Institute Journal - August 13, 2021 Category: Cardiology Authors: Daniel W Nelson Sakthi Sundararajan Evan Klein Lyle D Joyce Lucian A Durham David L Joyce Asim A Mohammed Source Type: research
Determinants of atrial fibrillation after cardiac surgery
Rev Cardiovasc Med. 2021 Jun 30;22(2):329-341. doi: 10.31083/j.rcm2202040.ABSTRACTPost-operative Atrial fibrillation (POAF) is a common complication post cardiac surgery. It can result in detrimental short- and long-term outcomes due to the increased risk of stroke, cardiac arrest and congestive heart failure in addition to prolonged intensive care and total hospital stay raising the overall healthcare cost. Accurately identifying predictors and biomarkers for POAF ensures that patients at greatest risk can be given the appropriate prophylactic measures; resources can be distributed to the groups who are most in need and w...
Source: Reviews in Cardiovascular Medicine - July 14, 2021 Category: Cardiology Authors: Mashal Qureshi Ammaarah Ahmed Victoria Massie Ellenor Marshall Amer Harky Source Type: research
